|
Atopix reports positive results from Phase IIb asthma study with OC459 compound
News-Medical.net Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma … |
View full post on asthma – Google News